Accueil   Diary - News   All news ElsaLys Biotech obtains 1.57 million euros

ElsaLys Biotech obtains 1.57 million euros

ElsaLys Biotech announced today that the FUI (Fonds Unique Interministériel – Single Interministerial Fund) has granted a 1.57 million euros subsidy to the TYROMAB (TYROsine kinase receptor Monoclonal AntiBody) project.

 

Led by a consortium headed by ElsaLys Biotech,this project seeks to validate and industrially produce an anti-TYRO3 antibody candidate for the treatment of leiomyosarcoma and metastatic bladder cancer. This should lead to two products: a candidate drug with an original mechanism of action in oncology and a new production system reducing monoclonal antibody production costs. Original in terms of its form and substance, this project provides a response to a twofold public health challenge: speeding up the development of new therapeutic antibodies against cancers and reducing their price, which notably entails decreasing their production cost.

 

 

Read the press release